Steris Plc (STE) Valuation

Based on the GoodMoat Investment Framework, Steris's valuation assessment is unfavourable. The primary tool, the DCF-derived GoodMoat Target of $172.02, indicates the stock's current price of $223.38 is approximately 30% above fair value. This results in a negative margin of safety, which fails the framework's requirement for a margin of safety of at least 20% to be considered favourable. The forward P/E of approximately 31x is high relative to the sector average for medical devices, which typically trades in the low-to-mid 20s, and appears elevated for a company with a 9.2% revenue growth rate, suggesting a high PEG ratio. While the company demonstrates moderate quality with a 12.1% profit margin and manageable debt, the valuation multiples do not provide the discount required for a value investor. The stock is priced for perfection, leaving no room for error or unforeseen challenges, which is a critical consideration given the framework's emphasis on a margin of safety. Analysis based on data as of 2024-05-15.